Crescent Capital BDC, Inc. announced a 19% dividend reduction Thursday, resetting its quarterly distribution to $0.34 per share from $0.42 as net investment income declined across the portfolio. The market response was immediate: shares now trade at a 39% discount to net asset value, the widest among SILVER-tier business development companies in our coverage universe and nearly double the sector median of 22%.
The cut reflects portfolio-level pressure. Management cited compressed spreads on floating-rate senior loans and elevated non-accruals in three middle-market credits, two in healthcare services and one in industrial distribution. Net investment income per share fell 14% year-over-year to $0.38 in the most recent quarter, leaving the prior $0.42 dividend undercovered by $0.04 per share. The board elected to reset rather than allow spillover income to erode further. Crescent held $47 million in undistributed taxable income at year-end, sufficient to cover approximately 2.1 quarters at the new rate, assuming stable NII.
The 39% NAV discount creates a valuation anomaly. Crescent's portfolio is 87% first-lien senior secured debt, with a weighted-average yield of 11.2% and non-accrual rate of 3.1% by fair value. Peer BDCs with similar credit profiles—Ares Capital, Golub Capital—trade at discounts between 8% and 15%. The gap suggests the market is pricing either asset quality deterioration beyond disclosed non-accruals or sustained dividend instability. Management's guidance implies NII stabilization at $0.36 to $0.38 per share over the next two quarters, which would restore modest coverage at the new $0.34 payout.
Two near-term catalysts could compress the discount. First, Crescent is positioned to redeploy $120 million in pending loan repayments into higher-yielding direct originations by mid-Q2, potentially lifting NII by $0.03 to $0.04 per share. Second, the BDC's investment advisor, Crescent Capital Group, has historically supported NAV through co-investment in stressed credits; allocators will watch whether the advisor steps in to stabilize the three non-accrual positions or allows them to resolve through restructuring. Management has signaled a preference for asset sales over prolonged workouts, with resolution timelines of four to seven months for the two healthcare credits.
The 39% discount is the fact. At $8.15 per share versus $13.37 NAV, the market assigns zero value to management's track record and negative value to the recalibrated dividend policy. Crescent's next earnings call is scheduled for May 7th.